Last10K.com

Acasti Pharma Inc. (ACST) SEC Filing 425 Merger Prospectus

SEC Filings

ACST Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

ACST Annual Reports

ACST Quarterly Reports

ACST Corporate News

ACST Corporate News

ACST Merger Prospectus

Acasti Pharma Inc.

HISTORY TOOLS
CIK: 1444192 Ticker: ACST

View differences made from one to another to evaluate Acasti Pharma Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 425 Merger Prospectus to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acasti Pharma Inc..

Continue

Assess how Acasti Pharma Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acasti Pharma Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools
Ticker: ACST
CIK: 1444192
Form Type: 425 Merger Prospectus
Accession Number: 0001171843-21-004980
Submitted to the SEC: Wed Jul 21 2021 5:15:25 PM EST
Accepted by the SEC: Wed Jul 21 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/acst/0001171843-21-004980.htm